Literature DB >> 7699396

Plasma levels of nitrates in patients with Parkinson's disease.

J A Molina1, F J Jiménez-Jiménez, J A Navarro, E Ruiz, J Arenas, F Cabrera-Valdivia, A Vázquez, P Fernández-Calle, L Ayuso-Peralta, M Rabasa.   

Abstract

It has been suggested that nitric oxide (NO) could be implicated in the neuronal degeneration of substantia nigra compacta in patients with Parkinson's disease (PD). To ascertain the possible role of NO as risk factor for PD, we studied the plasma levels of nitrate (oxidation product that provides an indirect estimation of NO), in 68 PD patients and 68 matched-controls. The plasma levels of nitrate did not differ significantly between PD patient and control groups (44.5 +/- 2.46 and 44.8 +/- 2.67 mumol/l, respectively). They were not influenced by antiparkinsonian drug and they did not correlate with age at onset, duration, scores of the Unified Parkinson's Disease Rating scales and Hoehn and Yahr staging in the PD group. These data suggest that plasma levels of nitrate are apparently unrelated to the risk for PD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7699396     DOI: 10.1016/0022-510x(94)90139-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.

Authors:  Bruno L Santos-Lobato; Mariza Bortolanza; Lucas César Pinheiro; Marcelo E Batalhão; Ângela V Pimentel; Evelin Capellari-Carnio; Elaine A Del-Bel; Vitor Tumas
Journal:  J Neural Transm (Vienna)       Date:  2021-12-23       Impact factor: 3.575

2.  Iron and inflammation: in vivo and post-mortem studies in Parkinson's disease.

Authors:  Antonio Martin-Bastida; Bension Shlomo Tilley; Sukhi Bansal; Steve M Gentleman; David T Dexter; Roberta J Ward
Journal:  J Neural Transm (Vienna)       Date:  2020-10-20       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.